Transient mRNA CAR T cells targeting GD2 provide dose-adjusted efficacy against diffuse midline glioma and high-grade glioma models.

Foster JB, Madsen PJ, Harvey K, Griffin C, Stern A, Patterson L, Joshi N, Dickson C, McManus O, Beaubien E, Wilson C, Beale DR, Baubet V, Goel PN, Vitanza NA, Nazarian J, Koptyra M, Storm PB, Resnick AC

Open source

DOI: 10.1093/neuonc/noaf115
Published: 2025 Oct 1
Container: Neuro-oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/neuonc/noaf115,
  title = {Transient mRNA CAR T cells targeting GD2 provide dose-adjusted efficacy against diffuse midline glioma and high-grade glioma models.},
  author = {Foster JB and Madsen PJ and Harvey K and Griffin C and Stern A and Patterson L and Joshi N and Dickson C and McManus O and Beaubien E and Wilson C and Beale DR and Baubet V and Goel PN and Vitanza NA and Nazarian J and Koptyra M and Storm PB and Resnick AC},
  year = {2025},
  journal = {Neuro-oncology},
  doi = {10.1093/neuonc/noaf115},
  url = {https://doi.org/10.1093/neuonc/noaf115}
}

RIS

TY  - JOUR
TI  - Transient mRNA CAR T cells targeting GD2 provide dose-adjusted efficacy against diffuse midline glioma and high-grade glioma models.
AU  - Foster JB
AU  - Madsen PJ
AU  - Harvey K
AU  - Griffin C
AU  - Stern A
AU  - Patterson L
AU  - Joshi N
AU  - Dickson C
AU  - McManus O
AU  - Beaubien E
AU  - Wilson C
AU  - Beale DR
AU  - Baubet V
AU  - Goel PN
AU  - Vitanza NA
AU  - Nazarian J
AU  - Koptyra M
AU  - Storm PB
AU  - Resnick AC
PY  - 2025
JO  - Neuro-oncology
DO  - 10.1093/neuonc/noaf115
UR  - https://doi.org/10.1093/neuonc/noaf115
ER  -

APA

JB, F., PJ, M., K, H., C, G., A, S., L, P., N, J., C, D., O, M., E, B., C, W., DR, B., V, B., PN, G., NA, V., J, N., M, K., PB, S., & AC, R. (2025). Transient mRNA CAR T cells targeting GD2 provide dose-adjusted efficacy against diffuse midline glioma and high-grade glioma models.. Neuro-oncology. https://doi.org/10.1093/neuonc/noaf115

Source records

pubmed · retrieved 2026-09-26T18:48:52.742Z
europe-pmc · retrieved 2026-09-26T18:48:52.757Z